THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Respiratory syncytial virus (RSV) is a common viral infection ... you should be vaccinated between your 32nd and 36th week to protect your baby, if this interval occurs between September and ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

But there’s another virus out there that can also cause these symptoms: It’s called respiratory syncytial virus (RSV ... and it protects the baby for their first RSV season.

The RSV vaccine protects against RSV (respiratory syncytial virus), a common seasonal virus ... that get shared with the fetus, protecting a baby during the first six months of life when the ...

Use saline drops and a bulb syringe to clear mucus from your baby's nose. Avoid respiratory ... ones from this common but potentially serious virus. 1. Jain H, Schweitzer JW, Justice NA. Respiratory ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...